Nanexa: NEX-22, partner projects, and Novo Nordisk evaluation prioritized - Redeye

Redeye updates its view of Nanexa following the Q4 report and recent events in the company. The report offered no surprises and we reiterate our stance that 2024 will be an important year for the company, as we hope for a breakthrough related to its partner deals and NEX-22 clinical trial.

Länk till analysen i sin helhet: https://www.redeye.se/research/983637/nanexa-nex-22-partner-projects-and-novo-nordisk-evaluation-prioritized?utm_source=finwire&utm_medium=RSS